Manager TitleAgeSince
Chief Executive Officer 66 22/02/2024
Chief Executive Officer 57 30/01/2017
Director TitleAgeSince
Director/Board Member 57 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-6.68%-18.17% - - 822K
-3.00%+2.27%+77.60%+109.33% 72.12B
+1.90%+23.53%+56.60%+97.76% 65.85B
+5.12%+25.22%+5.24%-0.82% 29.28B
+0.55%+1.64%-5.15%+471.68% 27.47B
+2.74%+12.98%+62.84%+28.14% 26.7B
+0.47%+6.12%+36.66%-13.79% 20.06B
+1.82%-6.67%+247.46%+393.10% 18.22B
+0.94%+3.36%+18.55%+532.94% 16.4B
+0.73%+5.54%+39.71%+153.07% 13.4B
Average +0.46%+8.36%+59.94%+196.82% 32.17B
Weighted average by Cap. +0.74%+9.48%+59.05%+157.80%

Financials

2021 2022
Net sales 6.2M 5.31M 4.97M 4.55M 8.54M 593M 8.65M 58.71M 22.9M 298M 23.28M 22.77M 986M 1.5M 1.28M 1.2M 1.1M 2.07M 144M 2.09M 14.2M 5.54M 72.1M 5.63M 5.51M 238M
Net income -9.7M -8.31M -7.78M -7.12M -13.36M -929M -13.54M -91.9M -35.84M -466M -36.44M -35.65M -1.54B -24.97M -21.39M -20.02M -18.32M -34.39M -2.39B -34.84M -236M -92.22M -1.2B -93.77M -91.73M -3.97B
Net Debt - -
Logo Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Inc is a United States-based company. The Company operates as a biopharmaceutical company focused on discovering and developing cellular immunotherapies for various forms of cancer.
Employees
13